MCM
ABUS icon

MAI Capital Management’s Arbutus Biopharma ABUS Stock Holding History

MAI Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.95K Buy
655
+54
+9% +$236 ﹤0.01% 3767
2025
Q4 		$2.89K Hold
601
– – ﹤0.01% 3317
2025
Q3 		$2.73K Hold
601
– – ﹤0.01% 3231
2025
Q2 		$1.86K Buy
+601
New +$2K ﹤0.01% 3446

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

MAI Capital Management's ABUS Position: Q1 2026 in Review

MAI Capital Management increased its Arbutus Biopharma (ABUS) stake by 9% in Q1 2026, buying an estimated $236 and bringing the position to 655 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #3767.

MAI Capital Management first reported a position in ABUS in Q2 2025 and has held it in 4 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • MAI Capital Management held 655 shares of Arbutus Biopharma worth $2.95K as of Q1 2026.
  • MAI Capital Management bought 54 Arbutus Biopharma shares in Q1 2026, an estimated $236.
  • Arbutus Biopharma made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3767 holding.
  • MAI Capital Management first reported a position in Arbutus Biopharma in Q2 2025 and has held it in 4 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.